Inovio Pharmaceuticals has signed an agreement with Transgene and ChronTech Pharma to jointly evaluate a therapeutic vaccination strategy against genotype 1 hepatitis C virus (HCV) in a phase I trial.
The clinical study, which will start later this year, is set to use ChronTech's ChronVac-C plasmid DNA vaccine delivered in vivo electroporation using Inovio's Medpulser DNA Delivery System (DDS) as the initial vaccination, followed by Transgene's therapeutic vaccine TG4040, a modified vaccinia Ankara (MVA).
Inovio's MedPulser DDS device delivers electrical pulses, enhancing cell membrane permeability, cellular uptake of the DNA vaccine and gene expression.
In previous trials the ChronVac-C DNA vaccine and the TG4040 were found to be safe and more immunogenic than those observed when they were injected separately.
The ChronVac-C plasmid DNA vaccine delivered by in vivo electroporation using the Medpulser was reported to be safe and generated antigen-specific immune responses and antiviral effects in a phase I/IIa trial.
Each partner will contribute its products and equally share costs related to the study, which will enroll 12 treatment-naive patients with chronic hepatitis C at a German site.